The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma
Dean A. Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the findings of a Phase II multi-center UK trial evaluating vinorelbine plus active supportive care versus active supportive care in patients with malignant pleural mesothelioma who had progressed after first-line chemotherapy. This study met its primary endpoint, demonstrating the useful clinical efficacy of vinorelbine in relapsed malignant pleural mesothelioma. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
